PMEF
KNSA icon

Point72 Middle East FZE’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Point72 Middle East FZE’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,218
Closed -$425K – 722
2023
Q4 		$425K Buy
+24,218
New +$398K 0.01% 861
2023
Q3 		– Sell
-25,669
Closed -$361K – 1671
2023
Q2 		$361K Buy
+25,669
New +$344K 0.01% 867

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Middle East FZE's KNSA Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2024, closing a stake of 24,218 shares — an estimated $425K sold.

Point72 Middle East FZE first reported a position in KNSA in Q2 2023 and held it in 2 quarters. The position peaked at $425K in Q4 2023. 154 funds tracked by Wall St. Rank hold KNSA as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Kiniksa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 24,218 Kiniksa Pharmaceuticals shares in Q1 2024, an estimated $425K.
  • Point72 Middle East FZE first reported a position in Kiniksa Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's Kiniksa Pharmaceuticals position peaked at $425K in Q4 2023.
  • 154 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.